Skip to content
Screener

Personalis, Inc. PSNL Cash & Equivalents

Cash & Equivalents at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$626M+96.2%
NeoGenomics logo
NeoGenomicsNEO
$145.54M-5.9%
Illumina logo
IlluminaILMN
$1.04B+11.3%
Veracyte logo
VeracyteVCYT
$264.79M+41.0%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$30M+44.7%
Guardant Health logo
Guardant HealthGH
$1.1B+37.0%

Other financials

Income statement

See full
Revenue$15.5M-24.9%
Gross profit$281.0K-96.1%
Operating income-$32.2M-81.7%
Net income-$30.0M-90.7%
EPS (diluted)-$0.29-61.1%

Balance sheet

See full
Total debt$39.0M-6.2%
Total equity$254.8M+22.9%
Total assets$325.4M+19.1%

Cash flow

See full
Operating cash flow-$22.5M-25.1%
CapEx$3.2M+27.1%
Free cash flow-$25.7M-25.4%

Valuation

See full
Market cap$1.39B+258%
Enterprise value$1.36B+261%
P/S21.6×+16.7×

Profitability

See full
Gross margin13.7%-19.6pp
Operating margin-158.9%-5,457pp
Net margin-148.1%+154pp
FCF margin-131.2%-453pp

Returns & leverage

See full
Return on equity-41.4%-6.7pp
Debt / equity0.2×0.0×
Current ratio6.6×-0.3×

Where this comes from

Reported directly by Personalis, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Personalis, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211896
Line itemMarch 31, 2026December 31, 2025
Assets
Current assets
Cash and cash equivalents$73,594$124,245
Short-term investments159,624115,708
Accounts receivable, net (1)13,02216,203
Inventory and other deferred costs6,9306,144
Prepaid expenses and other current assets5,0285,651
Total current assets258,198267,951

Item 1. Financial Statements

FAQ

What is Personalis, Inc.'s cash & equivalents?
Personalis, Inc. (PSNL) reported cash & equivalents of $73.59M in Q1 2026.
How has Personalis, Inc.'s cash & equivalents changed year-over-year?
Personalis, Inc.'s cash & equivalents increased by 3.7% year-over-year, from $71M to $73.59M.
What is the long-term trend for Personalis, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Personalis, Inc.'s cash & equivalents has grown at a 12.6% compound annual growth rate (CAGR), from $68.53M to $124.25M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Personalis, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude